Infinity cuts research jobs after lead drug disappoints in Phase II
American firm Infinity Pharma (Nasdaq: INFI) has been rocked by disappointing results from Phase II trials of its lead candidate Dynamo (duvelisib), leading the Massachusetts-based biotech to announce the closure of its discovery research organization, and placing the continuation of its collaboration with US drug major AbbVie (NYSE: ABBV) in doubt.
Although Dynamo as a monotherapy met its primary endpoints in the trial, the drug failed to provide as large a benefit to non-Hodgkin lymphoma patients as Infinity had hoped.
The overall response rate (ORR) of the 129 subjects enrolled in the trial was just 46%, and these patients all obtained only a partial response from the therapy- a dual inhibitor of phosphoinositide-3- kinase (PI3K)-delta and PI3K-gamma.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze